Sign in Subscribe
Genetic research

Gastric Cancer Study Reveals New Biomarker for Predicting Survival Outcomes

Strategic Insights

— 2 min read

Researchers from Tianjin Medical University have made a significant breakthrough in understanding the absorption, distribution, metabolism, and excretion (ADME) processes that govern drug disposition in the body. According to a study published in Discover Oncology, a novel ADME gene signature has been identified, which serves as a robust prognostic biomarker for evaluating the survival outcomes of gastric cancer patients.

The researchers established a prognostic model incorporating ADME-related genes to forecast the survival rate and therapeutic response in gastric cancer patients. By integrating Cox regression and LASSO analysis, a stable five-gene signature with significant prognostic value was identified. The nomogram incorporating these genes was constructed and integrated with a clinicopathological feature prediction system to improve its clinical applicability.

The study revealed a robust correlation between ADME-related genes and the survival outcomes of gastric cancer patients. The ADME-based gene signature serves as a robust prognostic biomarker for evaluating the survival outcomes. Moreover, immune cell infiltration and functional analyses demonstrated distinct patterns between the two strata, with the high-risk stratum exhibiting superior drug sensitivity.

Key Takeaways:

  • Researchers from Tianjin Medical University have identified a novel ADME gene signature, which serves as a robust prognostic biomarker for evaluating the survival outcomes of gastric cancer patients.
  • The study established a prognostic model incorporating ADME-related genes to forecast the survival rate and therapeutic response in gastric cancer patients.
  • A stable five-gene signature with significant prognostic value was identified through Cox regression and LASSO analysis.
  • The nomogram incorporating these genes was constructed and integrated with a clinicopathological feature prediction system to improve its clinical applicability.
  • The study revealed a robust correlation between ADME-related genes and the survival outcomes of gastric cancer patients.
  • Immune cell infiltration and functional analyses demonstrated distinct patterns between the two strata, with the high-risk stratum exhibiting superior drug sensitivity.
  • In vitro validation experiments using AGS and HGC-27 cell lines confirmed that elevated CYP2A6 expression promotes the progression of gastric cancer.
  • CYP2A6 may be a new biomarker in the therapeutic management of gastric cancer.

Statistics:

  • 5 genes were identified as significant prognostic value through Cox regression and LASSO analysis.
  • 2 cell lines (AGS and HGC-27) were used in in vitro validation experiments.
  • 1 new biomarker (CYP2A6) was identified in the therapeutic management of gastric cancer.
  • 1 journal (Discover Oncology) published the research findings.
  • The study was conducted at Tianjin Medical University.
  • The research was led by Xuejian Wang, Dept. of Orthopedics, Tianjin Medical University Baodi Hospital.

Sources:

  • NewsRx. Reports Outline Gastric Cancer Study Results from Tianjin Medical University (Development of an ADME gene signature for prognostic and therapeutic stratification in gastric cancer). Cancer Weekly. October 28, 2025; p 2869.
  • Discover Oncology. Development of an ADME gene signature for prognostic and therapeutic stratification in gastric cancer. 2025;16(1):1888.

Read more